Advances in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis/Mycosis.
4 affiliations
- 1The Institute of Medical Sciences, Tokai University, Isehara, Japan.
- 2Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Japan. [email protected].
- 3Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Japan.
- 4Department of Clinical Pharmacology, Tokai University School of Medicine, Isehara, Japan.
Abstract
Allergic bronchopulmonary aspergillosis/mycosis (ABPA/ABPM) is an immunologically mediated pulmonary disorder triggered by the colonization of filamentous fungi in the airways of patients with asthma or cystic fibrosis, leading to type I and III hypersensitivity responses, eosinophilic mucus plug formation, and central bronchiectasis. Over the past decade, advances in basic and clinical research have substantially reshaped the understanding and management of this disease. Although Aspergillus species, particularly Aspergillus fumigatus, remain the predominant causative fungi, epidemiological studies have identified Schizophyllum commune as an important and previously underrecognized pathogen responsible for ABPM. A major breakthrough in elucidating disease pathophysiology is the recognition of eosinophil extracellular trap cell death as a central mechanism driving highly viscous mucus impaction. Diagnostic criteria with improved accuracy and standardized treatment protocols have been established through randomized controlled trials, culminating in the 2024 revision of the International Society for Human and Animal Mycology guidelines. However, significant unmet needs remain. Despite high initial response rates to corticosteroids or azole antifungals, nearly half of patients fail to achieve remission. Predictors of treatment failure include heightened A. fumigatus-specific sensitization and radiological evidence of eosinophilic mucus impaction. Biologic agents targeting type 2 inflammation have emerged as promising options for difficult-to-treat disease, although their efficacy in acute ABPA is still uncertain. Frequent exacerbations also pose a major challenge, and the potential benefits of maintenance inhaled antifungals and environmental interventions are under investigation. Collectively, advances in pathophysiology, diagnostics, and therapeutics are transforming ABPA/ABPM management, yet substantial gaps persist in improving long-term outcomes. Trial Registration: ClinicalTrials.gov Identifier: NCT04442269.
Related
- Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis
- Treatment Impact on Inflammatory Markers in Patients with Asthma and Allergic Bronchopulmonary Aspergillosis
- Longitudinal changes in type 2 and Aspergillus-specific biomarkers during omalizumab therapy for allergic bronchopulmonary aspergillosis: a 36-week study in Chinese patients
- Clinical research advances in pulmonary infections in 2025: a narrative review of multipathogen assessment, precision diagnosis, and integrated management
- Duchenne muscular dystrophy-associated cardiomyopathy: advances in diagnosis and management
BibTeX
@article{asano2026advances,
title = {{Advances in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis/Mycosis.}},
author = {Koichiro Asano and Naoki Okada and Jun Tanaka and Katsuyoshi Tomomatsu and Yoshiki Shiraishi and Tsuyoshi Oguma},
journal = {Allergy, asthma \& immunology research},
year = {2026},
month = sep,
doi = {10.4168/aair.2026.18.5.626},
url = {https://europepmc.org/article/MED/42845221},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Advances in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis/Mycosis.
AU - Koichiro Asano
AU - Naoki Okada
AU - Jun Tanaka
AU - Katsuyoshi Tomomatsu
AU - Yoshiki Shiraishi
AU - Tsuyoshi Oguma
PY - 2026
DA - 2026/09/01
JO - Allergy, asthma & immunology research
DO - 10.4168/aair.2026.18.5.626
UR - https://europepmc.org/article/MED/42845221
AB - Allergic bronchopulmonary aspergillosis/mycosis (ABPA/ABPM) is an immunologically mediated pulmonary disorder triggered by the colonization of filamentous fungi in the airways of patients with asthma or cystic fibrosis, leading to type I and III hypersensitivity responses, eosinophilic mucus plug formation, and central bronchiectasis. Over the past decade, advances in basic and clinical research have substantially reshaped the understanding and management of this disease. Although Aspergillus species, particularly Aspergillus fumigatus, remain the predominant causative fungi, epidemiological studies have identified Schizophyllum commune as an important and previously underrecognized pathogen responsible for ABPM. A major breakthrough in elucidating disease pathophysiology is the recognition of eosinophil extracellular trap cell death as a central mechanism driving highly viscous mucus impaction. Diagnostic criteria with improved accuracy and standardized treatment protocols have been established through randomized controlled trials, culminating in the 2024 revision of the International Society for Human and Animal Mycology guidelines. However, significant unmet needs remain. Despite high initial response rates to corticosteroids or azole antifungals, nearly half of patients fail to achieve remission. Predictors of treatment failure include heightened A. fumigatus-specific sensitization and radiological evidence of eosinophilic mucus impaction. Biologic agents targeting type 2 inflammation have emerged as promising options for difficult-to-treat disease, although their efficacy in acute ABPA is still uncertain. Frequent exacerbations also pose a major challenge, and the potential benefits of maintenance inhaled antifungals and environmental interventions are under investigation. Collectively, advances in pathophysiology, diagnostics, and therapeutics are transforming ABPA/ABPM management, yet substantial gaps persist in improving long-term outcomes. Trial Registration: ClinicalTrials.gov Identifier: NCT04442269.
SN - 2092-7355
SN - 2092-7363
ER -